Emerging synthetic cannabinoids and the risk of psychosis: a growing concern for public health

Affiliations

¹ Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil. Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, SP, Brazil. Early Intervention in Psychosis Service (GAPi), Universidade Federal de São Paulo, São Paulo, SP, Brazil.
² Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, SP, Brazil. Associação Paulista para o Desenvolvimento da Medicina, São Paulo, SP, Brazil.
³ Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, SP, Brazil. Early Intervention in Psychosis Service (GAPi), Universidade Federal de São Paulo, São Paulo, SP, Brazil.

Editorial

José Diogo R Souza et al. Braz J Psychiatry. 2023 Jul-Aug.

. 2023 Jul-Aug;45(4):306-307.

doi: 10.47626/1516-4446-2023-0051. Epub 2023 Jun 12.

¹ Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil. Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, SP, Brazil. Early Intervention in Psychosis Service (GAPi), Universidade Federal de São Paulo, São Paulo, SP, Brazil.
² Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, SP, Brazil. Associação Paulista para o Desenvolvimento da Medicina, São Paulo, SP, Brazil.
³ Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, SP, Brazil. Early Intervention in Psychosis Service (GAPi), Universidade Federal de São Paulo, São Paulo, SP, Brazil.

No abstract available

Conflict of interest statement

The authors report no conflicts of interest.

1. Hobbs M, Kalk NJ, Morrison PD, Stone JM. Spicing it up ‐ synthetic cannabinoid receptor agonists and psychosis ‐ a systematic review. Eur Neuropsychopharmacol. 2018;28:1289. - PubMed
1. Deng H, Verrico CD, Kosten TR, Nielsen DA. Psychosis and synthetic cannabinoids. Psychiatry Res. 2018;268:400–12. - PubMed
1. Winstock A, Lynskey M, Borschmann R, Waldron J. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol. 2015;29:698–703. - PubMed
1. Van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 2015;29:254–63. - PubMed
1. Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol. 2010;92:370–85. - PubMed